title: Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance.
abstract: Oral immunomodulatory drugs (IMiDs), namely thalidomide, lenalidomide and pomalidomide, interfere with several pathways important for disease progression. Today they play a crucial role in the treatment of multiple myeloma patients, and have considerably improved myeloma outcomes. These agents, and thalidomide in particular, are associated with higher rates of thromboembolic events, both venous and arterial. Individual risk factors for thromboembolic events include advanced age, previous history of thromboembolism, an indwelling central venous catheter, comorbid conditions (e.g. infections, diabetes, cardiac disease, obesity), current or recent immobilization, recent surgery and inherited thrombophilic abnormalities. Cancer therapy and cancer itself also increase the risk of thromboembolic events. The aim of this review is to help clinicians to define the risk of thrombotic events in patients treated with thalidomide and thus to provide practical recommendations to manage thromboprophylaxis in these patients.
authors.affiliation: Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Torino, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
authors.affiliation: Myeloma Unit, Division of Hematology, University of Torino, AOU San Giovanni Battista, Torino, Italy.
authors.forename: Carmela
authors.initials: C
authors.lastname: Palladino
keywords: aspirin; heparin; multiple myeloma; novel agents; thalidomide; thromboprophylaxis; venous thromboembolism; warfarin
references.citation: Lancet. 2000 Apr 15;355(9212):1295-302
references.pmid: 10776741
references.citation: Arch Intern Med. 2000 Mar 27;160(6):809-15
references.pmid: 10737280
references.citation: Thromb Haemost. 2003 Sep;90(3):446-55
references.pmid: 12958614
references.citation: Br J Haematol. 2003 Aug;122(4):607-16
references.pmid: 12899716
references.citation: J Clin Oncol. 2006 Jan 20;24(3):431-6
references.pmid: 16365178
references.citation: Expert Rev Anticancer Ther. 2007 Mar;7(3):307-15
references.pmid: 17338651
references.citation: J Clin Oncol. 2007 Dec 1;25(34):5490-505
references.pmid: 17968019
references.citation: J Clin Oncol. 2003 Jan 1;21(1):16-9
references.pmid: 12506164
references.citation: Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9
references.pmid: 10639148
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3664-70
references.pmid: 19451428
references.citation: Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8
references.pmid: 16344099
references.citation: Arch Intern Med. 2002 Jun 10;162(11):1245-8
references.pmid: 12038942
references.citation: Semin Thromb Hemost. 2003 Jun;29(3):275-82
references.pmid: 12888931
references.citation: Leukemia. 2008 Aug;22(8):1485-93
references.pmid: 18528426
references.citation: Blood. 2010 Jul 8;116(1):2-3
references.pmid: 20616223
references.citation: Ann Intern Med. 2001 Sep 4;135(5):367-73
references.pmid: 11529700
references.citation: Br J Haematol. 2005 Jun;129(6):763-70
references.pmid: 15953002
references.citation: Lancet Oncol. 2005 Jun;6(6):401-10
references.pmid: 15925818
references.citation: Cancer. 2004 Aug 1;101(3):558-66
references.pmid: 15274069
references.citation: Circulation. 2008 Jan 29;117(4):e25-146
references.pmid: 18086926
references.citation: N Engl J Med. 2006 Mar 9;354(10):1021-30
references.pmid: 16525139
references.citation: BMJ. 1994 Nov 5;309(6963):1213-5
references.pmid: 7987155
references.citation: Hematology Am Soc Hematol Educ Program. 2006;:348-55
references.pmid: 17124082
references.citation: Thromb Haemost. 2005 Aug;94(2):362-5
references.pmid: 16113826
references.citation: Eur Heart J. 2007 Jul;28(13):1598-660
references.pmid: 17569677
references.citation: Br J Haematol. 2004 Sep;126(5):715-21
references.pmid: 15327525
references.citation: Blood. 2001 Jul 15;98(2):492-4
references.pmid: 11435324
references.citation: Arch Intern Med. 1999 Mar 8;159(5):445-53
references.pmid: 10074952
references.citation: Arch Intern Med. 1998 Mar 23;158(6):585-93
references.pmid: 9521222
references.citation: J Natl Compr Canc Netw. 2010 Feb;8 Suppl 1:S13-20
references.pmid: 20141670
references.citation: Circulation. 2010 Feb 23;121(7):e46-e215
references.pmid: 20019324
references.citation: Leukemia. 2004 Apr;18(4):856-63
references.pmid: 14973508
references.citation: Am J Med. 1993 Sep;95(3):315-28
references.pmid: 8368229
references.citation: Blood. 2010 Sep 2;116(9):1405-12
references.pmid: 20448107
references.citation: J Clin Oncol. 2010 Dec 1;28(34):5101-9
references.pmid: 20940200
references.citation: Eur J Haematol. 2005 Apr;74(4):293-6
references.pmid: 15777340
references.citation: N Engl J Med. 2003 Oct 30;349(18):1695-702
references.pmid: 14585937
references.citation: Lancet. 2006 Mar 11;367(9513):825-31
references.pmid: 16530576
references.citation: JAMA. 2005 Feb 9;293(6):715-22
references.pmid: 15701913
references.citation: Eur J Haematol. 2011 Jan;86(1):16-22
references.pmid: 20942865
references.citation: Leuk Lymphoma. 2005 Feb;46(2):239-42
references.pmid: 15621807
references.citation: Clin Cancer Res. 2002 Nov;8(11):3377-82
references.pmid: 12429624
references.citation: J Am Coll Cardiol. 2005 Sep 20;46(6):937-54
references.pmid: 16168274
references.citation: J Thromb Haemost. 2004 Feb;2(2):327-34
references.pmid: 14995997
references.citation: Lancet. 2007 Oct 6;370(9594):1209-18
references.pmid: 17920916
references.citation: Leukemia. 2008 Feb;22(2):414-23
references.pmid: 18094721
references.citation: Br J Haematol. 2011 Jul;154(1):76-103
references.pmid: 21517805
references.citation: Ann Intern Med. 2004 Jun 1;140(11):867-73
references.pmid: 15172900
references.citation: Cancer. 2012 Jan 15;118(2):549-57
references.pmid: 21720994
references.citation: Mayo Clin Proc. 2005 Dec;80(12):1568-74
references.pmid: 16342649
references.citation: N Engl J Med. 2001 Jun 21;344(25):1951-2
references.pmid: 11419443
references.citation: Leuk Lymphoma. 2007 Dec;48(12):2330-7
references.pmid: 18067007
references.citation: N Engl J Med. 2003 Jul 10;349(2):109-11
references.pmid: 12853582
references.citation: Ann Hematol. 2004 Sep;83(9):588-91
references.pmid: 15235749
references.citation: Cancer Control. 2003 Sep-Oct;10(5):375-83
references.pmid: 14581892
references.citation: Haematologica. 2006 Feb;91(2):252-4
references.pmid: 16461313
references.citation: J Am Acad Dermatol. 1996 Dec;35(6):969-79
references.pmid: 8959957
references.citation: J Clin Oncol. 2010 Jul 1;28(19):3160-6
references.pmid: 20516439
references.citation: J Thromb Haemost. 2006 Jul;4(7):1470-5
references.pmid: 16839339
references.citation: Curr Hematol Rep. 2003 Sep;2(5):388-94
references.pmid: 12932310
references.citation: Ann Hematol. 2005 May;84(5):311-6
references.pmid: 15605244
references.citation: Semin Thromb Hemost. 2006 Oct;32(7):651-8
references.pmid: 17024592
references.citation: Hematol J. 2004;5(2):112-7
references.pmid: 15048060
references.citation: J Clin Oncol. 2011 Mar 10;29(8):986-93
references.pmid: 21282540
references.citation: Blood. 2008 Apr 15;111(8):3968-77
references.pmid: 18245666
references.citation: J Clin Oncol. 2003 Dec 1;21(23):4444-54
references.pmid: 14645435
references.citation: Orthopedics. 2009 Dec;32(12 Suppl):79-84
references.pmid: 20201481
references.citation: Mayo Clin Proc. 2003 Jan;78(1):34-9
references.pmid: 12528875
references.citation: Chest. 2008 Jun;133(6 Suppl):160S-198S
references.pmid: 18574265
references.citation: AAPS J. 2005 Mar 22;7(1):E14-9
references.pmid: 16146335
references.citation: Leukemia. 2003 Apr;17(4):775-9
references.pmid: 12682636
references.citation: Hematology Am Soc Hematol Educ Program. 2010;2010:437-44
references.pmid: 21239832
references.citation: Haematologica. 2006 Jun;91(6):862-3
references.pmid: 16769594
references.citation: Arch Intern Med. 2000 Dec 11-25;160(22):3415-20
references.pmid: 11112234
references.citation: Ann Oncol. 2001 Jul;12(7):885-6
references.pmid: 11521791
references.citation: Hematol J. 2002;3(4):185-92
references.pmid: 12189564